Biodexa Pharmaceuticals (BDRX) Enterprise Value (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) reported Enterprise Value of -$11.4 million for Q4 2025, down 429.91% on a YoY basis from $3.4 million in Q4 2024, and down 110.83% sequentially from -$5.4 million in Q2 2025.
Biodexa Pharmaceuticals (BDRX) Enterprise Value (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 13 years of Enterprise Value data on file, last reported at -$11.4 million in Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 429.91% year-over-year to -$11.4 million; the trailing twelve-month figure through Dec 2025 stood at -$11.4 million (down 429.91% YoY), and the FY2025 full-year result was -$11.3 million, down 425.27% from the prior year.
- Enterprise Value eased to -$11.4 million in Q4 2025, from -$5.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.1 million in Q4 2024 to a low of -$13.6 million in Q4 2021.
- A 5-year average of -$7.0 million and a median of -$6.5 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 75.46% in 2022 and tumbled 429.91% in 2025, its largest moves.
- Tracing BDRX's Enterprise Value over 5 years: stood at -$13.6 million in 2021, then surged by 75.46% to -$3.3 million in 2022, then sank by 122.79% to -$7.4 million in 2023, then surged by 71.09% to -$2.1 million in 2024, then plunged by 429.91% to -$11.4 million in 2025.
- Business Quant data shows BDRX's Enterprise Value at -$11.4 million in Q4 2025, -$5.4 million in Q2 2025, and -$2.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -1.91 Bn |
| 10 | Biodexa Pharmaceuticals | 17.56 Bn | 17.54 Bn | - | -11.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.35 Mn |
| Jun 30, 2025 | -5.38 Mn |
| Dec 31, 2024 | -2.14 Mn |
| Jun 30, 2024 | -6.38 Mn |
| Dec 31, 2023 | -7.41 Mn |
| Jun 30, 2023 | -6.54 Mn |
| Dec 31, 2022 | -3.33 Mn |
| Jun 30, 2022 | -8.09 Mn |
| Dec 31, 2021 | -13.56 Mn |
| Jun 30, 2021 | -5.88 Mn |
| Dec 31, 2020 | -9.96 Mn |
| Jun 30, 2020 | -5.37 Mn |
| Dec 31, 2019 | -14.05 Mn |
| Jun 30, 2019 | -11.55 Mn |
| Dec 31, 2018 | -3.01 Mn |
| Jun 30, 2018 | -5.61 Mn |
| Dec 31, 2017 | -17.53 Mn |
| Jun 30, 2017 | -7.90 Mn |
| Dec 31, 2016 | -21.89 Mn |
| Jun 30, 2016 | -10.38 Mn |